Clinical outcomes of transcatheter aortic valve implantation in patients younger than 70 years rejected for surgery: the AMTRAC registry

Guy Witberg*, Uri Landes, Pablo Codner, Marco Barbanti, Roberto Valvo, Ole De Backer, Joris F. Ooms, Angela McInerney, Giulia Masiero, Paul Werner, Xavier Armario, Claudia Fiorina, Dabit Arzamendi, Sandra Santos-Martinez, Jose A. Baz, Klemen Steblovnik, Victor Mauri, Matti Adam, Ilan Merdler, Manuel HeinPhilipp Ruile, Marco Russo, Francesco Musumeci, Alexander Sedaghat, Atsushi Sugiura, Carmelo Grasso, Luca Branca, Rodrigo Estévez-Loureiro, Ignacio J. Amat-Santos, Darren Mylotte, Martin Andreas, Matjaž Bunc, Giuseppe Tarantini, Luis Nombela-Franco, Lars Sondergaard, Nicolas M. Van Mieghem, Ariel Finkelstein, Ran Kornowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The mean age of transcatheter aortic valve implantation (TAVI) patients is steadily decreasing. Aims: The aim of the study was to describe the characteristics, the indications for and the outcomes of TAVI in patients <70 years old. Methods: All patients undergoing TAVI (n=8,626) from the 18 participating centres between January 2007 and June 2020 were stratified by age (</>70). For patients <70, the indications for TAVI were extracted from Heart Team discussions and the baseline characteristics and mortality were compared between the two groups. Results: Overall, 640 (7.4%) patients were <70 (9.1% during 2018-2020, p<0.001); the mean age was 65.0±2.3 years. The younger patients were more often male, with bicuspid valves or needing valve-in-valve procedures. They had a higher prevalence of lung disease and diabetes. In 80.7% of cases, the Heart Team estimated an increased surgical risk and TAVI was selected, reflected by an STS score >4% in 20.4%. Five-year mortality was similar (29.4 vs 29.8%, HR 0.95, p=0.432) in the <70 and >70 groups. In the <70 group, mortality was higher for those referred for TAVI due to an increased surgical risk compared to those referred for other reasons (31.6 vs 24.5%, HR 1.23, p=0.021). Mortality was similar regardless of the STS stratum in patients judged by the Heart Team to be at increased surgical risk (32.6 vs 30.4%, HR 0.98, p=0.715). Conclusions: Use of TAVI in patients <70 is becoming more frequent. The main reason for choosing TAVI is due to an increased surgical risk not adequately represented by the STS score. The outcomes for these patients are similar to those for older TAVI patients. Dedicated trials of TAVI/SAVR in younger patients are needed to guide decisions concerning expansion of TAVI indications.

Original languageEnglish
Pages (from-to)1289-1297
Number of pages9
Issue number16
StatePublished - Mar 2022


  • TAVI
  • multidisciplinary Heart Team
  • risk stratification


Dive into the research topics of 'Clinical outcomes of transcatheter aortic valve implantation in patients younger than 70 years rejected for surgery: the AMTRAC registry'. Together they form a unique fingerprint.

Cite this